- $520.64m
- $415.98m
- $7.00m
Annual income statement for Evommune, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | USG | USG |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 5 | 7 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Total Operating Expenses | 42.9 | 77 |
| Operating Profit | -37.9 | -70 |
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -34.1 | -66.8 |
| Net Income After Taxes | -34.1 | -66.8 |
| Net Income Before Extraordinary Items | ||
| Net Income | -34.1 | -66.8 |
| Adjustments to Net Income | ||
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -34.1 | -68.3 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -1.13 | -2.27 |